Immunome (IMNM) Net Equity Issued and Repurchased (2020 - 2025)
Immunome's (IMNM) quarterly Net Equity Issued and Repurchased came in at $432400.0 in Q4 2025, down 97.84% YoY from $20.0 million in Q4 2024, and down 99.04% on a QoQ basis from $44.9 million in Q3 2025.
Immunome (IMNM) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Immunome (IMNM) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $432400.0 in Q4 2025.
- Quarterly Net Equity Issued and Repurchased fell 97.84% year-over-year to $432400.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $65.3 million (down 54.94% YoY) and the FY2025 annual result came in at $45.9 million, up 129.48% from the prior year.
- Net Equity Issued and Repurchased fell to $432400.0 in Q4 2025, from $44.9 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $125.0 million in Q2 2023 to a low of $34000.0 in Q1 2023.
- A 4-year average of $27.3 million and a median of $801000.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased sank 89.45% — and 2025, when it sank 97.84%.
- Tracing IMNM's Net Equity Issued and Repurchased over 4 years: stood at $801000.0 in 2021, then jumped by 15505.49% to $125.0 million in 2023, then tumbled by 84.0% to $20.0 million in 2024, then slumped by 97.84% to $432400.0 in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $432400.0 (Q4 2025), $44.9 million (Q3 2025), and $20.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 432,400.00 |
| Dec 31, 2025 | 432,400.00 |
| Sep 30, 2025 | 44.90 Mn |
| Sep 30, 2025 | 44.90 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Dec 31, 2024 | 20.00 Mn |
| Jun 30, 2023 | 125.00 Mn |
| Jun 30, 2023 | 125.00 Mn |
| Mar 31, 2023 | 34,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Jun 30, 2021 | 801,000.00 |
| Jun 30, 2021 | 801,000.00 |
| Mar 31, 2021 | 105,000.00 |
| Mar 31, 2021 | 105,000.00 |
| Jun 30, 2020 | 11.00 Mn |
| Jun 30, 2020 | 11.00 Mn |
| Mar 31, 2020 | 995,000.00 |
| Mar 31, 2020 | 995,000.00 |